Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: Positive staining for cyclin A as a poor prognostic indicator

Human Pathology

Volumn 34, Issue 5, 2003, Pages 471-478

  Shih, Hsien chang ^b   Shiozawa, Tanri ^a   Kato, Kiyoshi ^b   Imai, Tsutomu ^b   Miyamoto, Tsutomu ^b   Uchikawa, Junko ^b   Nikaido, Toshio ^b   Konishi, Ikuo ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Cyclin; Cyclin dependent kinase; Endometrial carcinoma; Immunohistochemistry; Prognosis

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; CYCLINE; GENE PRODUCT; KI 67 ANTIGEN; PROTEIN KINASE; PROTEIN P21; PROTEIN P27; PROTEIN P53; SEX HORMONE; STEROID RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CELL CYCLE; CELL GROWTH; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; ENZYME ANALYSIS; FEMALE; GROWTH REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; STAINING; TUMOR SUPPRESSOR GENE;

EID: 0038620340     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(03)00124-2     Document Type: Article

References (27)

1. Kurman RJ, Zaino RJ, Norris HJ: Endometrial carcinoma, in Kurmann RJ, (ed): Blaustein's Pathology of the Female Genital Tract. (ed 4). New York, Springer-Verlag, 1994, pp 447-448
2. Barakat RR, Grisby PW, Sabbatini P, et al: Corpus: Epithelial tumors, in Hoskins WJ, Perez CA, Young RC, (eds): Principles and Practice of Gynecologic Oncology. ed 3. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 919-959
3. Sherr CJ: G1 phase progression: Cyclin on cue. Cell 79:551- 555, 1994
4. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995
5. Hartwell LH, Kasten MB: Cell cycle control and cancer. Science 266:1821-1828, 1994
6. Crompton NE, Saydan N: Control of the cell cycle. J Neurooncol 22:255-259, 1999
7. Dictor M, Ehinger M, Mertens F, et al: Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 112:40-52, 1999
8. Hetzel DJ, Wilson TO, Keeney GL, et al: HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 47:179-185, 1992
9. Creasman WT: Prognostic significance of hormone receptors in endometrial cancer. Cancer 71:1467-1470, 1993
10. Wagatsuma S, Konno R, Sato S, et al: Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 82:520-530, 1998
11. Burton JL, Wells M: Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 33:297-303, 1998
12. Li SF, Shiozawa T, Nakayama K, et al: Stepwise abnormality of sex steroid hormone receptors, tumor-suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 77:321-329, 1996
13. Shiozawa T, Lu X, Nikaido T, et al: Immunohistochemical detection of cyclin A with reference to p53 expression in human endometrial endometrioid carcinoma. Int J Gynecol Pathol 16:348-353, 1997
14. Shiozawa T, Nikaido T, Shimizu M, et al: Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 80:2250-2256, 1997
15. Shiozawa T, Li SF, Nakayama K, et al: Relationship between the expression of cyclins/cyclin-dependent kinases and sex-steroid receptors/Ki-67 in normal human endometrial glands and stroma during the menstrual cycle. Mol Hum Reprod 2:745-752, 1996
16. Koshiyama M, Konishi I, Fujii S: Review: Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer. Cancer J 11:277-283, 1998
17. Yamamoto M, Yoshida M, Ono K, et al: Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression. Exp Cell Res 210:94-101, 1994
18. Luciani MG, Hutchins JR, Zheleva D, et al: The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 300:503-518, 2000
19. Guadagno TM, Ohtsubo M, Roberts JM, et al: A link between cyclin A expression and adhesion-dependent cell cycle progression. Science 262:1572-1575, 1993
20. McLaughlin CL: Principles of chemotherapy, in Cameron RB, (ed): Practical Oncology. Los Angeles, CA, Prentice-Hall, 1994, pp 9-11
21. Eifel PJ: Radiation therapy, in Berek JS, Hacker NF, (eds): Practical Gynecologic Oncology (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 118-131
22. Huuhtanen RL, Wiklund TA, Blomqvist CP, et al: A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients. Br J Cancer 81:1017-1021, 1999
23. Hsieh JK, Yap D, O'Connor DJ, et al: Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 22:78-93, 2002
24. Ito K, Sasano H, Matsunaga G, et al: Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183:318-324, 1997
25. Fredersdorf S, Burns J, Milne AM, et al: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 94:6380-6385, 1997
26. Kip1 in the normal squamous epithelium, CIN and invasive squamous cell carcinoma of the uterine cervix. Cancer 92: 3005-3011, 2001
27. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1996